SCARFONE, GIOVANNA
SCARFONE, GIOVANNA
Universita' degli Studi di MILANO
A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxe/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and IV ovarian cancer (OC)
2006 G. Scarfone, G. Scambia, F. Raspagliesi, G. Mangili, S. Danese, M. Presti, F. Petruzzelli, B. Costa, G. Bolis
A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy
1999 G. Scarfone, A. Villa, F. Parazzini, C. Sciatta, G. Polverino, G. Bolis
A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, C. Sciatta, G.P. Polverino, C. Rosa, P. Guarnerio, F. Parazzini
Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer
2001 G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini
Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study
2014 G. Scarfone, A. Bergamini, S. Noli, A. Villa, S. Cipriani, G. Taccagni, P. Vigano', M. Candiani, F. Parazzini, G. Mangili
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
2020 T. Vandenbroucke, M. Verheecke, M. van Gerwen, K. Van Calsteren, M.J. Halaska, M. Fumagalli, R. Fruscio, A. Gandhi, M. Veening, L. Lagae, P.B. Ottevanger, J.-. Voigt, J. de Haan, M.M. Gziri, C. Maggen, L. Mertens, G. Naulaers, L. Claes, F. Amant, J. Blommaert, J. Dekrem, F. Goffin, V. Rigo, C. Fontana, F. Mosca, S. Passera, O. Picciolini, G. Scarfone, F.A. Peccatori, M.L. Boffi, M. Delle Marchette, R. Nacinovich, C. Lok, V. Wolters, I. Boere, E. Witteveen, C. Schroder, C. de Groot, M. van Grotel, M. van den Heuvel-Eibrink, A. Babkova, V. Drochytek
Clear cell and papillary serous endometrial carcinomas : survival in a series of 128 cases
2013 G. Scarfone, R. Secomandi, F. Parazzini, R. Viganò, G. Mangili, L. Frigerio, A. Villa, S. Tateo, E. Ricci, G. Bolis
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
2003 M.S. Aapro1, F.H. van Wijk, G. Bolis, B. Chevallier, M.E.L. van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. Nooij, M. Presti, C. Scarabelli, T.A.W. Splinter, E. Ploch, L.V.A. Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P.G. Harper, C. Madronal, M. Namer, G. Scarfone, J.E.G.M. Stoot, I. Teodorovic, C. Coens, I. Vergote, J.B. Vermorken
Effects of in-utero exposure to chemotherapy on fetal brain growth
2019 S. Passera, V. Contarino, G. Scarfone, E. Scola, C. Fontana, F. Peccatori, C. Cinnante, S. Counsell, M. Ossola, S. Pisoni, N. Pesenti, E. Grossi, F. Amant, F. Mosca, F. Triulzi, M. Fumagalli
Epidemiology of breast cancer in young women
2015 F. Parazzini, A. Villa, G. Polverino, S. Noli, G. Scarfone
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report
2021 G. Scarfone, M. Fumagalli, M. Imbimbo, T. Ceruti, F.M. Cribiu, E. Di Loreto, M. D'Incalci, F. Facchin, C. Fontana, M.C. Garassino, F.A. Peccatori, N. Persico, D. Signorelli, M. Zucchetti
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
2003 J.B. Trimbos, I. Vergote, G. Bolis, J.B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, L. Giurgea, P. Timmers, C. Coens, S. Pecorelli
Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers
2013 S. Noli, S. Cipriani, G. Scarfone, A.G. Villa, E. Grossi, E. Monti, P. Vercellini, F. Parazzini
Obstetric and Neonatal Outcomes in Women with Pregnancy Associated Cancer: a population-based Study in Lombardy, Northern Italy
2021 G. Esposito, M. Franchi, M. Dalmartello, G. Scarfone, E. Negri, F. Parazzini, C. La Vecchia, G. Corrao
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
2000 C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, C. Mangioni, V. Lucchini, F. Vecchione, G. Bolis, G. Scarfone, F. Zunino
Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial
2004 G. Bolis, G. Scarfone, G. Polverino, F. Raspagliesi, S. Tateo, G. Richiardi, M. Melpignano, M. Franchi, G. Mangili, M. Presti, A. Villa, E. Conta, P. Guarnerio, S. Cipriani, F. Parazzini
Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer
1999 G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, S. Reina, E. Pirletti
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study
2010 G. Bolis, G. Scarfone, F. Raspagliesi, G. Mangili, S. Danese, P. Scollo, D. Lo Russo, A. Villa, P. D. Aimone, G. Scambia
Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, A. Villa, F. Parazzini
Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel
2001 G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, F. Parazzini